FR-260010

From WikiMD's WELLNESSPEDIA

FR-260010































FR-260010 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily of interest in the field of cardiovascular pharmacology due to its action as a potassium channel opener. This compound has been investigated for its ability to induce vasodilation and its potential therapeutic applications in treating conditions such as hypertension and angina pectoris.

Pharmacodynamics[edit]

FR-260010 functions by opening ATP-sensitive potassium channels (K_ATP channels) in vascular smooth muscle cells. This action leads to hyperpolarization of the cell membrane, which in turn causes relaxation of the smooth muscle and vasodilation. The opening of these channels reduces intracellular calcium levels, further contributing to muscle relaxation.

Pharmacokinetics[edit]

The pharmacokinetic profile of FR-260010 includes its absorption, distribution, metabolism, and excretion. Studies have shown that it is rapidly absorbed when administered orally, with a bioavailability that allows for effective plasma concentrations to be reached. The compound is metabolized primarily in the liver, and its metabolites are excreted via the renal route.

Clinical Applications[edit]

While FR-260010 has shown promise in preclinical studies, its clinical applications are still under investigation. The primary focus has been on its use as an antihypertensive agent and in the management of ischemic heart conditions. However, further clinical trials are necessary to fully establish its efficacy and safety profile.

Side Effects[edit]

Potential side effects of FR-260010, as with other potassium channel openers, may include hypotension, dizziness, and headache. These effects are generally related to its vasodilatory action.

Research and Development[edit]

Research on FR-260010 is ongoing, with studies focusing on its mechanism of action, therapeutic potential, and safety. The compound is part of a broader class of drugs being explored for their cardiovascular benefits.

Also see[edit]

References[edit]


This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.